<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04762784</url>
  </required_header>
  <id_info>
    <org_study_id>tocilizumab treatment for IRPF</org_study_id>
    <nct_id>NCT04762784</nct_id>
  </id_info>
  <brief_title>A Prospective Study of Tocilizumab in the Treatment of Idiopathic Retroperitoneal Fibrosis</brief_title>
  <official_title>A Prospective, Controlled, Interventional Study to Evaluate the Efficacy and Safety of Tocilizumab in the Treatment of Idiopathic Retroperitoneal Fibrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking Union Medical College Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking Union Medical College Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective study to investigate the treatment response of Tocilizumab on patients&#xD;
      with idiopathic retroperitoneal fibrosis（IRPF）.&#xD;
&#xD;
      Methods: All the patients fulfilling diagnostic criteria of IRPF would be enrolled. The IRPF&#xD;
      patients will accept Tocilizumab or Glucocorticoid monotherapy for 3 months.&#xD;
&#xD;
      Endpoints: The primary endpoint is to investigate the response of Tocilizumab on IRPF&#xD;
      patients; the secondary endpoints include the decrease of inflammatory markers, side effect.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2020</start_date>
  <completion_date type="Anticipated">February 10, 2023</completion_date>
  <primary_completion_date type="Anticipated">February 10, 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>remission</measure>
    <time_frame>5 years</time_frame>
    <description>Remission is achieved when symptoms are alleviated and laboratory tests return to normal levels or radiologic improvement is observed.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>relapse</measure>
    <time_frame>5 years</time_frame>
    <description>Participants have recurrence of symptoms and laboratory abnormalities.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>adverse events</measure>
    <time_frame>5 years</time_frame>
    <description>Participants suffer from adverse events due to the drug treatment</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Idiopathic Retroperitoneal Fibrosis</condition>
  <arm_group>
    <arm_group_label>Tocilizumab treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tocilizumab is a recombinant humanized monoclonal antibody against human interleukin-6 (IL-6) receptor. Tocilizumab acts by inhibiting the activity of IL-6 receptor. IL-6 is a pro-inflammatory cytokine whose release can trigger a series of downstream pro-inflammatory responses. Tocilizumab inhibits IL-6 signal transduction by blocking the binding of IL-6 to soluble and membrane-bound IL-6 receptors, thereby reducing pathological inflammatory responses.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Glucocorticoids monotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Glucocorticoids has fast onset of action and multiple anti-inflammatory effects.The conventional protocol is oral prednisone, followed by a slow tapering over 4 weeks. Besides, precautionary measures need to be taken against possible complications brought by the application of corticosteroids such as infections, diabetes mellitus, hypertension, Cushing's syndrome and osteoporosis, etc.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tocilizumab</intervention_name>
    <description>Tocilizumab treatment: Tocilizumab infusion 8mg/Kg，Once per month for 3 months.</description>
    <arm_group_label>Tocilizumab treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glucocorticoids</intervention_name>
    <description>Prednisone/prednisolone: started at 0.6-0. 8mg/kg.d for 2 to 4 weeks, tapered at 5mg per 1-2 weeks to equal to or less than 15mg per day in 3 months.</description>
    <arm_group_label>Glucocorticoids monotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  age 18-75 diagnosed as IRPF: The diagnosis of idiopathic retroperitoneal fibrosis is&#xD;
             based on the following aspects :(1) the swelling of retroperitoneal tissue , which&#xD;
             seems neoplastic; (2) A large number of lymphocytes proliferated and infiltrated in&#xD;
             the affected tissues and organs, and tissues showed inflammation, fibrosis and&#xD;
             sclerosis, in which IgG4-positive cells accounted for less than 50% of plasma cells;&#xD;
             (3) Increased inflammatory markers, such as ESR and CRP; (4) Good response to&#xD;
             glucocorticoid therapy.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  malignancy retroperitoneal fibrosis secondary to other diseases or drug treatment or&#xD;
             abdominal surgeries.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Peking Union Medical College Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yunyun Fei</last_name>
      <phone>+8613681125226</phone>
      <email>feiyunyun2013@sina.com</email>
    </contact>
    <contact_backup>
      <last_name>Wen Zhang</last_name>
      <email>zhangwen91@sina.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Marzano A, Trapani A, Leone N, Actis GC, Rizzetto M. Treatment of idiopathic retroperitoneal fibrosis using cyclosporin. Ann Rheum Dis. 2001 Apr;60(4):427-8.</citation>
    <PMID>11247880</PMID>
  </reference>
  <reference>
    <citation>Schultz O, Schuchmann S, Burmester GR, Buttgereit F. Case number 26: systemic idiopathic fibrosis associated with aortitis. Ann Rheum Dis. 2003 May;62(5):486.</citation>
    <PMID>12695167</PMID>
  </reference>
  <reference>
    <citation>Summaries for patients. Tamoxifen for the treatment of retroperitoneal fibrosis. Ann Intern Med. 2006 Jan 17;144(2):I51.</citation>
    <PMID>16418405</PMID>
  </reference>
  <reference>
    <citation>van Bommel EF, Hendriksz TR, Huiskes AW, Zeegers AG. Brief communication: tamoxifen therapy for nonmalignant retroperitoneal fibrosis. Ann Intern Med. 2006 Jan 17;144(2):101-6.</citation>
    <PMID>16418409</PMID>
  </reference>
  <reference>
    <citation>Vaglio A, Salvarani C, Buzio C. Retroperitoneal fibrosis. Lancet. 2006 Jan 21;367(9506):241-51. Review.</citation>
    <PMID>16427494</PMID>
  </reference>
  <reference>
    <citation>Vaglio A, Greco P, Buzio C. Tamoxifen therapy for retroperitoneal fibrosis. Ann Intern Med. 2006 Apr 18;144(8):619; author reply 619-20.</citation>
    <PMID>16618960</PMID>
  </reference>
  <reference>
    <citation>Jagadesham VP, Scott DJ, Carding SR. Abdominal aortic aneurysms: an autoimmune disease? Trends Mol Med. 2008 Dec;14(12):522-9. doi: 10.1016/j.molmed.2008.09.008. Epub 2008 Nov 6. Review.</citation>
    <PMID>18980864</PMID>
  </reference>
  <reference>
    <citation>Qian Q, Kashani KB, Miller DV. Ruptured abdominal aortic aneurysm related to IgG4 periaortitis. N Engl J Med. 2009 Sep 10;361(11):1121-3. doi: 10.1056/NEJMc0905265.</citation>
    <PMID>19741239</PMID>
  </reference>
  <reference>
    <citation>Scheel PJ Jr, Feeley N, Sozio SM. Combined prednisone and mycophenolate mofetil treatment for retroperitoneal fibrosis: a case series. Ann Intern Med. 2011 Jan 4;154(1):31-6. doi: 10.7326/0003-4819-154-1-201101040-00005.</citation>
    <PMID>21200036</PMID>
  </reference>
  <reference>
    <citation>Swartz R, Scheel P. Retroperitoneal fibrosis: gaining traction on an enigma. Lancet. 2011 Jul 23;378(9788):294-6. doi: 10.1016/S0140-6736(11)60880-5. Epub 2011 Jul 4.</citation>
    <PMID>21733569</PMID>
  </reference>
  <reference>
    <citation>Vaglio A, Palmisano A, Alberici F, Maggiore U, Ferretti S, Cobelli R, Ferrozzi F, Corradi D, Salvarani C, Buzio C. Prednisone versus tamoxifen in patients with idiopathic retroperitoneal fibrosis: an open-label randomised controlled trial. Lancet. 2011 Jul 23;378(9788):338-46. doi: 10.1016/S0140-6736(11)60934-3. Epub 2011 Jul 4.</citation>
    <PMID>21733570</PMID>
  </reference>
  <reference>
    <citation>Binder M, Uhl M, Wiech T, Kollert F, Thiel J, Sass JO, Walker UA, Peter HH, Warnatz K. Cyclophosphamide is a highly effective and safe induction therapy in chronic periaortitis: a long-term follow-up of 35 patients with chronic periaortitis. Ann Rheum Dis. 2012 Feb;71(2):311-2. doi: 10.1136/annrheumdis-2011-200148. Epub 2011 Aug 22.</citation>
    <PMID>21859695</PMID>
  </reference>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>February 17, 2021</study_first_submitted>
  <study_first_submitted_qc>February 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 21, 2021</study_first_posted>
  <last_update_submitted>March 17, 2021</last_update_submitted>
  <last_update_submitted_qc>March 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking Union Medical College Hospital</investigator_affiliation>
    <investigator_full_name>Wen Zhang</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>idiopathic retroperitoneal fibrosis</keyword>
  <keyword>Tocilizumab</keyword>
  <keyword>Response</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Retroperitoneal Fibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glucocorticoids</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

